|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/357 | |
| A61K 31/519 | |||
| A61K 31/555 | |||
| A01N 43/58 | |||
| A61K 45/06 | |||
| A61P 35/00 |
| (11) | Patento numeris | 3148336 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 15799685.1 |
| Europos patento paraiškos padavimo data | 2015-05-28 | |
| (97) | Europos patento paraiškos paskelbimo data | 2017-04-05 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-10-02 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2015/032990 |
| Data | 2015-05-28 |
| (87) | Numeris | WO 2015/184145 |
| Data | 2015-12-03 |
| (30) | Numeris | Data | Šalis |
| 201462003798 P | 2014-05-28 | US | |
| 201462088200 P | 2014-12-05 | US |
| (72) |
COX, David, US
KREMER, Alton, US
MCGONIGLE, Sharon, US
WU, Jiayi, US
|
| (73) |
Eisai R&D Management Co., Ltd.,
6-10, Koishikawa 4-chome Bunkyo-ku, Tokyo 112-8088,
JP
|
| (54) | ERIBULIN AND POLY (ADP RIBOSE) POLYMERASE (PARP) INHIBITORS AS COMBINATION THERAPY FOR THE TREATMENT OF CANCER |
| ERIBULIN AND POLY (ADP RIBOSE) POLYMERASE (PARP) INHIBITORS AS COMBINATION THERAPY FOR THE TREATMENT OF CANCER |